Immvira is an oncology immunotherapy innovator focused on dual oncolytic and immune-directed treatments, developing next-generation oncolytic virus products and herpesvirus-based therapeutic tumor vaccines. The company positions itself as a platform biotech for clinically driven drug-carrier development, including an OvPENS discovery/development platform. It currently has three product pipelines that have entered clinical stages. Immvira plans clinical trials in both China and the U.S. to evaluate single-agent and combination regimens of those pipelines. The firm also intends to pursue IND filings for its oncolytic virus and exosome product lines and to develop and validate new candidates derived from OvPENS. The article lists a founder/CEO with a PhD from the Shanghai Institute of Biochemistry (Chinese Academy of Sciences) and multiple academic and translational-medicine leadership roles. ImmVira Group Company focuses on developing next-generation oncolytic herpes simplex virus (oHSV) therapies to improve viral replication, oncolytic activity, and anti-tumor immune responses. The company currently pursues five developmental product lines, including an intratumoral oHSV (MVR-T3011) being studied as monotherapy or in combination, an intravenous oHSV for extensive metastatic tumors, oHSV candidates for malignant brain tumors, oncolytic-virus-resistant tumors, and targeted oHSV for hematological malignancies. Its intratumoral MVR-T3011 program has launched clinical studies in Australia, China and the United States. In August 2020 ImmVira and Shanghai Pharma announced a clinical collaboration and exclusive license agreement for commercialization of MVR-T3011. Grace Zhou serves as Chairman and CEO. The company recently completed a strategic Series B Plus financing of US$10m, reflecting current investor interest in its clinical programs. Immvira Group Company is a Shenzen, China-based biotechnology company focused on developing new-generation oncolytic viruses as potential cancer therapeutics. Led by Dr. Grace Zhou (chairman of the board and CEO), the company engineers viruses to improve replication, enhance oncolytic activity, and promote anti-tumor immune responses. Its oncolytic virus product T3 has launched clinical studies in Australia, China and the United States to explore treatment of multiple solid tumors. The company’s pipeline includes T3011 (intratumoral and systemic administration), C5252 for malignant brain tumors, and four additional planned products targeting lung cancer, liver cancer, virus-resistant solid tumors, and hematological malignancies. In June 2020 Immvira closed a $58M Series B to support preclinical and clinical development, discovery of new early-stage candidates, and potential strategic collaborations with domestic and global partners.

Total raised

$68M

Funding rounds

3

Latest round

Series B

Latest activity

Sep 2020